← Eichor
Condition: Small Cell Lung Cancer Metastatic Or Locally Advanced Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Small Cell Lung Cancer Metastatic Or Locally Advanced

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT07070440JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 26 location(s) · Teligene US · NCT05168566A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Phase 3 · 1 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT05989542A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan
Phase 3 · 351 location(s) · Mirati Therapeutics Inc. · NCT06875310A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 83 location(s) · AstraZeneca · NCT07098338ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · iLeukon Therapeutics, Inc. · NCT07452224A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet
Phase 2 · 71 location(s) · Bristol-Myers Squibb · NCT07680764Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC H
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT07336732A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06114511A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06355609A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-smal
Phase 3 · 29 location(s) · Nuvation Bio Inc. · NCT06564324A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05949606A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Xuanzhu Biopharmaceutical Co., Ltd. · NCT04996121A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Phase 2 · 25 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06496490AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Ot
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06505824A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Phase 2 · 5 location(s) · Abbisko Therapeutics Co, Ltd · NCT06668103
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.